Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck

Shots:

• AstraZeneca & Merck will utilize Myriads’ BRAC Analysis CDx to identify germline BRCA mutations in men who have mCRPC cancer, enrolled in Phase III PROfound (NCT02987543) study
• In 2007, Myriad collaborates with AZ for BRAC Analysis CDx to be used as a companion diagnostic to Lynparza (olaparib) and the combination has received approval from MHLW & FDA for different indications in oncology
• Myriad’s BRACAnalysis CDx is an in vitro diagnostic used for detection of germline BRCA1 and BRCA2 variant and provide a clinical interpretation of the identified variants. Myriad plans to file sPMA to FDA for BRACAnalysis CDx used as a companion diagnostic to Lynparza (olaparib) in mCRPC patients

Click here to read full press release/ article | Ref: Myriad | Image: Specialty Pharma Journal